A Compelling Approach

Today, healthcare services must be ready to deal not only with increased competition, but also the impact of more regulatory reform; meanwhile, the global life sciences industry, and in particular the pharmaceuticals sector, is facing increasing scrutiny from policymakers and competition authorities. Our experts in competition, litigation and policy matters in the health sector advise government and private sector clients in several countries, bringing our extensive experience from other sectors to healthcare. This means we apply lessons from working with companies that have historically been or are currently regulated, and leverage our unparalleled position in competition and litigious issues in a variety of sectors to healthcare, pharmaceuticals and life sciences. This ensures that we deliver clients the best and the most compelling solutions.

  • Merger advice including for pharmaceuticals, trusts and hospitals
  • Competition investigations, including those involving horizontal and vertical agreements and restraints and abuse of dominance
  • Advice on reforms in healthcare policy and regulation
  • Advice on patent disputes and other litigation and arbitrations
  • Efficiency analysis and benchmarking of healthcare providers
The Oxera CV
  • Advice to Mylan during its acquisition of Abbott Laboratories’ branded speciality and generics business in Europe
  • Provided competition risk assessment for a large NHS foundation trust during a potential merger
  • Advising two pharmaceuticals companies in the European Commission’s ongoing investigations into patent settlements involving Lundbeck and Servier
  • Advised Pinewood Healthcare in its claim for damages against Reckitt Benckiser following a finding of abuse of dominance in the market for Gaviscon
  • Advised AstraZeneca in responding to a claim for damages from a generic pharmaceutical firm lodged at the UK High Court
  • Advised a large pharmaceutical firm in a litigation involving refusal to supply
  • Advised competition authorities, hospitals and homecare services during merger inquiries and market investigations in Netherlands and South Africa
  • Contributed to the OFT’s market study into private healthcare services, with a report on the techniques used for market definition
  • Advised the National Health Service and Department of Health on reforms to healthcare in the UK; member of the panel advising Monitor, the new sector regulator
  • Advice to Monitor on a variety of regulatory issues, including regulatory coherence, cost-collection methodologies and appropriate cost of capital for setting tariffs
  • Reviewed the European Commission’s regulatory impact assessment for its proposed Tobacco Directive